Troutman Pepper advised Apnimed on the deal. Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related...
Apnimed’s Series C Financing
PharmaCyte Biotech’s $15 Million Follow-On Public Offering
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech, Inc. on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer...